Welcome to our dedicated page for Inflarx news (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on Inflarx stock.
InflaRx N.V. (Nasdaq: IFRX) is a biopharmaceutical company that regularly issues news on its clinical programs targeting the complement system, particularly the C5a/C5aR axis. Company updates highlight progress with its oral C5a receptor inhibitor izicopan (also referenced as INF904) and its intravenously delivered anti-C5a monoclonal antibody vilobelimab, including GOHIBIC (vilobelimab) for SARS-CoV-2-induced acute respiratory distress syndrome in the European Union.
News about InflaRx often covers clinical trial milestones, such as Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria for izicopan, as well as analyses of Phase 3 data for vilobelimab in pyoderma gangrenosum. Releases also describe regulatory interactions, including anticipated discussions with the U.S. Food and Drug Administration, and strategic decisions about prioritizing resources toward izicopan and adjusting spending on GOHIBIC (vilobelimab).
Investors following IFRX news can expect announcements on clinical data readouts, participation in healthcare and investor conferences, and business updates related to funding, cash runway and partnering activities. InflaRx’s communications have included information on BARDA-supported studies in acute respiratory distress syndrome, co-development activities for an anti-C5a antibody in China, and notices regarding Nasdaq listing requirements.
This news feed aggregates InflaRx’s press releases and related coverage so readers can review clinical developments, regulatory updates and corporate actions in one place. For those tracking complement-targeted therapeutics, IFRX news provides insight into how the company is advancing its C5a and C5aR inhibitor programs across dermatologic and respiratory indications and how it is aligning its strategy and capital allocation with these priorities.
InflaRx hosted a virtual R&D event showcasing their oral small molecule C5aR inhibitor, INF904. The event detailed its potential in treating Chronic Spontaneous Urticaria (CSU) and Hidradenitis Suppurativa (HS), both representing multi-billion-dollar markets. INF904's Phase 2a clinical trial for CSU and HS will start by late 2024, with results expected by summer 2025. The trial aims to evaluate safety, pharmacokinetics, and clinical benefits. InflaRx expects their strong financial position to fund operations into 2026, supporting further clinical advancements. The company sees INF904 as a pipeline-in-a-product, potentially addressing broader therapeutic areas.
InflaRx N.V. (Nasdaq: IFRX) presented new data at the ATS 2024 International Conference showing significant improvements in mortality rates for critically ill COVID-19 patients treated with vilobelimab in combination with tocilizumab or baricitinib. The analysis, derived from the PANAMO Phase III trial, demonstrates an 84.6% relative reduction in 28-day all-cause mortality and a 66.7% relative reduction in 60-day all-cause mortality compared to placebo. Safety assessments revealed no major concerns related to the combination therapy. This data further supports the FDA's emergency use authorization for vilobelimab in critically ill COVID-19 patients.
InflaRx N.V. reported financial results for Q1 2024 and provided updates on INF904 and Phase III vilobelimab trials. They highlighted plans to initiate Phase IIa in CSU and HS by 2024 end, with data availability in 2025. The vilobelimab trial for PG is ongoing, with an interim analysis in 2025. Cash reserves of €85.8 million expected to fund operations into 2026.
InflaRx N.V. (Nasdaq: IFRX) will report its first quarter 2024 financial and operating results on May 8, 2024. They will host a virtual R&D event on June 5, 2024, focusing on the development of their new oral small molecule C5aR inhibitor, INF904, and its potential in treating chronic spontaneous urticaria and hidradenitis suppurativa. Key opinion leaders will provide insights into the commercial opportunity and therapeutic potential of INF904.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.